Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Archer-Daniels-Midland Co (ADM) vs Novavax Inc (NVAX) Price & Performance

Archer-Daniels-Midland CoTrade
Novavax IncTrade

Price performance (Past 24H)

Key statistics

Archer-Daniels-Midland Co vs Novavax Inc — how do they compare? Archer-Daniels-Midland Co trades at $79.95 (market cap $38.78B), while Novavax Inc trades at $7.95 (market cap $1.31B). The key difference: Archer-Daniels-Midland Co is far larger — about 29.6× Novavax Inc's market cap, and Archer-Daniels-Midland Co pays a 2.59% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.

ADMNVAX
Market Cap
$38.78B$1.31B
Sector
Consumer StaplesHealth
52-Week High
$87.32$11.19
52-Week Low
$56.00$6.22
Enterprise Value
$47.03B$889.30M
Dividend Yield
2.59%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Archer-Daniels-Midland Co

ADM trades at $79.41, down 1.34% today, with a bullish technical signal and strong earnings beats in recent quarters. The company reported Q2 2026 EPS of $1.84, exceeding expectations, and raised its full-year outlook, driven by biofuels and crushing margins. Valuation ratios like P/E of 21.98 and P/S of 0.48 suggest reasonable pricing relative to peers. Cash flow improved in 2025 with net cash flow of $1.58 billion.

The outlook is positive with analyst consensus price target of $88.00, implying upside. Key opportunities include growth in AgTech and biofuels, while risks involve execution challenges and volatile commodity markets. The stock offers a dividend yield supported by consistent payments, but investors should monitor margin pressures from input costs.

Novavax Inc

Novavax (NVAX) trades at $7.97, up 1.01% with a mixed technical picture showing bullish overall signals but bearish moving averages. The company reported strong Q2 2026 results, beating revenue and earnings estimates while raising full-year guidance. Despite negative profitability metrics, valuation ratios appear attractive with P/E of 3.14 and EV/EBITDA of 1.72. Recent news highlights progress with Sanofi partnership and cost reduction initiatives.

The outlook remains challenged by negative cash flows and accumulated deficits, but analyst sentiment is positive with 74% buy ratings. Key risks include ongoing operational losses and vaccine demand volatility, while potential upside exists from partnership milestones and adjuvant platform expansion. The stock presents a high-risk opportunity with significant analyst support despite fundamental weaknesses.

Returns comparison

Trailing returns across standard periods

About Archer-Daniels-Midland Co

Archer-Daniels Midland is a major processor of oilseeds, corn, wheat, and other agricultural commodities. Additionally, the company owns an extensive network of logistical assets to store and transport crops around the globe. ADM also runs a nutrition business that focuses on both human and animal ingredients. The company is also a large producer of corn-based sweeteners, starches, and ethanol.

Read more on ADM

About Novavax Inc

Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.

Read more on NVAX